Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioma, Malignant: early-phase trial registry
14 of 20 indexed Glioma, Malignant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 14 currently recruiting · #848 of 28,707 conditions by registered trial count
Glioma, Malignant: 20 US clinical trials tracked, 14 recruiting.
Glioma, Malignant is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Nader Sanai, running 3 of these trials.
Enrollment posture brief
Registry condition glioma-malignant
OPEN 14 | RECR 70% | LATE 1 | EARLY 15 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Glioma, Malignant lists 14 open slots (70% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioma, Malignant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioma, Malignant is recruiting above its size-band peers.
14 of 20 indexed trials (70%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Glioma, Malignant research.
Nader Sanai accounts for 3 of 20 trials (15%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Glioma, Malignant trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 20 trials that report a genuine target (sentinel values excluded). 18 of those (90%) plan for fewer than 100 participants.
-
Glioma, Malignant research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics
NCT06810544
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Darell Bigner
NCT04547777
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals
NCT05226494
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Children's Hospital of Philadelphia
NCT05555550
18F-Fluciclovine PET-MRI in High-grade Glioma
Children's Hospital of Philadelphia
NCT05553041
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Baptist Health South Florida
NCT06397560
Window of Opportunity Study of DSP-0390 in Gliomas
Washington University School of Medicine
NCT06636162
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Northwestern University
NCT06169280
CUE-102 in Recurrent Glioblastoma
David Reardon, MD
NCT06917885
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT05773326
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Nader Sanai
NCT05182905
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT05283109
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
NCT05406700
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
NCT05393258
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Dana-Farber Cancer Institute
NCT04497142
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioma, Malignant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioma, Malignant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioma, Malignant page
20 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Glioma, Malignant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nader Sanai sponsors the most Glioma, Malignant trials on record, review their full trial history before evaluating a specific study. See Nader Sanai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioma, Malignant condition card totals 20 registered trials; most-linked intervention Niraparib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.